News & Events about Cullinan Oncology Inc.
CAMBRIDGE, Mass., Jan. 24, 2023 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc.(Nasdaq: CGEM), a biopharmaceutical company focused on modality-agnostic targeted oncology therapies, today announcedthe U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for ...
Globe Newswire
6 months ago
CAMBRIDGE, Mass., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan Oncology) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today announced that its Chief Financial Officer, Jeff Trigilio, ...
Globe Newswire
8 months ago
Updated data from Phase 1/2a study show median duration of response greater than 21 months and median progression-free survival of 12 months at 100 mg BID dose Confirmed overall response rate of 41% at 100 mg BID dose Continued favorable safety and tolerability profile observed in heavily pre-...
Globe Newswire
8 months ago
Meeting to highlight updated data from the Phase 1/2a study of CLN-081 CAMBRIDGE, Mass., May 26, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan) a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies for patients with cancer, today ...
Globe Newswire
8 months ago
Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417 Cullinan Oncology will receive an upfront cash payment of $275 million, with potential to receive up to an additional $130 ...